Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Hosp Pediatr ; 12(2): 190-198, 2022 02 01.
Article in English | MEDLINE | ID: mdl-35075483

ABSTRACT

BACKGROUND: The microbiologic etiologies, clinical manifestations, and antimicrobial treatment of neonatal infections differ substantially from infections in adult and pediatric patient populations. In 2019, the Centers for Disease Control and Prevention developed neonatal-specific (Standardized Antimicrobial Administration Ratios SAARs), a set of risk-adjusted antimicrobial use metrics that hospitals participating in the National Healthcare Safety Network's (NHSN's) antimicrobial use surveillance can use in their antibiotic stewardship programs (ASPs). METHODS: The Centers for Disease Control and Prevention, in collaboration with the Vermont Oxford Network, identified eligible patient care locations, defined SAAR agent categories, and implemented neonatal-specific NHSN Annual Hospital Survey questions to gather hospital-level data necessary for risk adjustment. SAAR predictive models were developed using 2018 data reported to NHSN from eligible neonatal units. RESULTS: The 2018 baseline neonatal SAAR models were developed for 7 SAAR antimicrobial agent categories using data reported from 324 neonatal units in 304 unique hospitals. Final models were used to calculate predicted antimicrobial days, the SAAR denominator, for level II neonatal special care nurseries and level II/III, III, and IV NICUs. CONCLUSIONS: NHSN's initial set of neonatal SAARs provides a way for hospital ASPs to assess whether antimicrobial agents in their facility are used at significantly higher or lower rates compared with a national baseline or whether an individual SAAR value is above or below a specific percentile on a given SAAR distribution, which can prompt investigations into prescribing practices and inform ASP interventions.


Subject(s)
Anti-Bacterial Agents , Hospitals , Adult , Anti-Bacterial Agents/therapeutic use , Centers for Disease Control and Prevention, U.S. , Child , Delivery of Health Care , Humans , Infant, Newborn , United States
2.
BMC Pediatr ; 12: 6, 2012 Jan 16.
Article in English | MEDLINE | ID: mdl-22248486

ABSTRACT

BACKGROUND: To evaluate the effects on serum 25(OH)D and bone mineralization of supplementation of breast-fed Hispanic and non-Hispanic Caucasian infants with vitamin D in infants in Houston, Texas. METHODS: We measured cord serum 25(OH)D levels, bone mineral content (BMC), bone mineral density (BMD) and their changes over 3 months of life with 400 IU/day of vitamin D3 supplementation. RESULTS: Cord serum 25(OH)D was significantly lower in Hispanic than non-Hispanic Caucasian infants (16.4 ± 6.5 ng/mL, n = 27, vs 22.3 ± 9.4 n = 22, p = 0.013). Among 38 infants who completed a 3 month vitamin D supplementation intervention, provision of 400 IU/day of vitamin D increased final 25(OH)D to a higher level in non-Hispanic Caucasian compared to Hispanic infants. There was no significant relationship between cord serum 25(OH)D and BMC or BMD in the first week of life (n = 49) or after 3 months of vitamin D supplementation. CONCLUSION: Low cord 25(OH)D levels are seen in Hispanic infants, but their functional significance is uncertain related to bone health in a southern US setting. Daily vitamin D intake of 400 IU during the first months of life appears adequate to increase serum 25(OH)D and support BMC increases despite low initial 25(OH)D levels in some infants. TRIAL REGISTRATION: ClincalTrials.gov NCT00697294.


Subject(s)
Bone Density , Fetal Blood/chemistry , Hispanic or Latino , Vitamin D/analogs & derivatives , White People , Biomarkers/blood , Humans , Infant , Infant, Newborn , Texas/ethnology , Vitamin D/administration & dosage , Vitamin D/blood , Vitamins/administration & dosage
3.
J Pediatr ; 158(6): 885-890.e1, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21300373

ABSTRACT

OBJECTIVE: To evaluate the effects of early bronchopulmonary dysplasia (BPD) on calcium (Ca) metabolism and growth in very low birth weight (VLBW) infants. STUDY DESIGN: A dual-tracer, stable isotope method was used to assess Ca absorption in VLBW infants. Infants with early BPD received energy-dense feedings and mild fluid restriction. RESULTS: Sixteen of 41 preterm infants were classified as having early BPD. Fractional Ca absorption (early BPD, 58.4 ± 4.6% versus no early BPD, 50.3 ± 4.0%, P = .2), total Ca absorption (early BPD, 127 ± 14 mg/kg/d versus no early BPD, 104 ± 9 mg/kg/d, P = .9), and Ca retention (early BPD, 99.6 ± 10.0 mg/kg/d versus no early BPD, 91.0 ± 9.8 mg/kg/d, P = .2) were similar among groups. There was no significant difference in weight gain, linear growth, or head circumference growth between groups. CONCLUSIONS: The ability of VLBW infants with early BPD and fluid restriction to grow and accrete calcium is similar to those without early BPD. The use of high caloric density feedings in VLBW infants with early BPD can help achieve bone and overall growth outcomes close to those achievable in utero.


Subject(s)
Bronchopulmonary Dysplasia/complications , Bronchopulmonary Dysplasia/metabolism , Calcium/pharmacokinetics , Infant, Very Low Birth Weight/metabolism , Absorption , Animals , Cattle , Humans , Infant Formula , Infant, Newborn , Infant, Premature , Intensive Care, Neonatal , Mass Spectrometry/methods , Milk , Milk, Human , Phosphorus/metabolism
4.
JPEN J Parenter Enteral Nutr ; 34(1): 32-7, 2010.
Article in English | MEDLINE | ID: mdl-19587385

ABSTRACT

BACKGROUND: Extremely few data are available about the natural history of parenteral nutrition (PN)-associated cholestasis. The authors evaluated a cohort of infants at a large center to determine the outcome of PN-associated cholestasis in infants with some gastrointestinal function. METHODS: The authors reviewed the records of all infants admitted to a level 3 neonatal intensive care unit over a 16-month period who had the diagnosis of PN-associated cholestasis. Records were reviewed in these infants for course of cholestasis, laboratory values, outcome, and infection rate. RESULTS: Sixty-six patients were admitted who met the study criteria. There were 10 deaths and 1 referral for liver transplant (Death/TPlant) (17%) in the first year of life. All Death/TPlant infants had at least 1 positive blood culture after the onset of cholestasis. Maximum conjugated bilirubin (MaxCB) in Death/TPlant infants was 15.7 +/- 2.2 (SEM) compared to 8.4 +/- 1.0 mg/dL in babies who recovered. Of 21 infants with a MaxCB > or =10.0, Death/TPlant occurred in 8/21 (38%). Of 40 babies with positive blood cultures, 11 were in the Death/TPlant group vs no deaths among the 25 without positive blood cultures. Average time to resolution from the MaxCB to a CB <2.0 mg/dL was 66 +/- 7 days (n = 49). CONCLUSIONS: Infants with PN-associated cholestasis have high rates of mortality despite the presence of some gastrointestinal function. These data support further evaluation and the development of novel forms of therapy for babies with parenteral-associated CB > or =2 mg/dL with emphasis on interventions for infants with a CB >10 mg/dL.


Subject(s)
Cholestasis/mortality , Parenteral Nutrition/adverse effects , Bilirubin/blood , Cholagogues and Choleretics/therapeutic use , Cholestasis/blood , Cholestasis/etiology , Humans , Incidence , Infant , Infant, Newborn , Infections/etiology , Intestinal Diseases/therapy , Liver Transplantation , Ursodeoxycholic Acid/therapeutic use
5.
Nutrients ; 2(3): 230-40, 2010 03.
Article in English | MEDLINE | ID: mdl-22254018

ABSTRACT

Substantial losses of nutrients may occur during tube (gavage) feeding of fortified human milk. Our objective was to compare the losses of key macronutrients and minerals based on method of fortification and gavage feeding method. We used clinically available gavage feeding systems and measured pre- and post-feeding (end-point) nutrient content of calcium (Ca), phosphorus (Phos), protein, and fat. Comparisons were made between continuous, gravity bolus, and 30-minute infusion pump feeding systems, as well as human milk fortified with donor human milk-based and bovine milk-based human milk fortifier using an in vitro model. Feeding method was significantly associated with fat and Ca losses, with increased losses in continuous feeds. Fat losses in continuous feeds were substantial, with 40 ± 3 % of initial fat lost during the feeding process. After correction for feeding method, human milk fortified with donor milk-based fortifier was associated with significantly less loss of Ca (8 ± 4% vs. 28 ± 4%, p< 0.001), Phos (3 ± 4% vs. 24 ± 4%, p < 0.001), and fat (17 ± 2% vs. 25 ± 2%, p = 0.001) than human milk fortified with a bovine milk-based fortifier (Mean ± SEM).


Subject(s)
Calcium, Dietary/analysis , Dietary Fats/analysis , Food, Fortified , Milk Proteins/analysis , Milk, Human/chemistry , Phosphorus, Dietary/analysis , Calcium, Dietary/administration & dosage , Dietary Fats/administration & dosage , Enteral Nutrition/instrumentation , Enteral Nutrition/methods , Humans , Milk Proteins/administration & dosage , Phosphorus, Dietary/administration & dosage
6.
BMC Pediatr ; 9: 47, 2009 Jul 29.
Article in English | MEDLINE | ID: mdl-19640269

ABSTRACT

BACKGROUND: Osteopenia and rickets are common among extremely low birth weight infants (ELBW, <1000 g birth weight) despite current practices of vitamin and mineral supplementation. Few data are available evaluating the usual course of markers of mineral status in this population. Our objectives in this study were to determine the relationship between birth weight (BW) and peak serum alkaline phosphatase activity (P-APA) in ELBW infants and evaluate our experience with the diagnosis of rickets in these infants. METHODS: We evaluated all ELBW infants admitted to Texas Children's Hospital NICU in 2006 and 2007. Of 211 admissions, we excluded 98 patients who were admitted at >30 days of age or did not survive/stay for >6 weeks. Bone radiographs obtained in 32 infants were reviewed by a radiologist masked to laboratory values. RESULTS: In this cohort of 113 infants, P-APA was found to have a significant inverse relationship with BW, gestational age and serum phosphorus. In paired comparisons, P-APA of infants <600 g (957 +/- 346 IU/L, n = 20) and infants 600-800 g (808 +/- 323 IU/L, n = 43) were both significantly higher than P-APA of infants 800-1000 g (615 +/- 252 IU/L, n = 50), p < 0.01. Thirty-two patients had radiographic evaluation for evidence of rickets, based on P-APA greater than 800 IU/L, parenteral nutrition greater than 3 to 4 weeks, or clinical suspicion. Of these, 18 showed radiologic rickets and 14 showed osteopenia without rickets. Infants with BW <600 g were more likely to have radiologic rickets (10/20 infants) compared to those with BW 600-800 g (6/43 infants) and BW 800-1000 g (2/50 infants), p < 0.01 for each. P-APA was not significantly higher in infants with radiologic rickets (1078 +/- 356 IU/L) compared to those without radiologic evidence of rickets (943 +/- 346, p = 0.18). CONCLUSION: Elevation of P-APA >600 IU/L was very common in ELBW infants. BW was significantly inversely related to both P-APA and radiologic rickets. No single value of P-APA was related to radiological findings of rickets. Given the very high risk of osteopenia and rickets among ELBW infants, we recommend consideration of early screening and early mineral supplementation, especially among infants <600 g BW.


Subject(s)
Alkaline Phosphatase/blood , Infant, Premature, Diseases/blood , Rickets/blood , Bone Diseases, Metabolic/blood , Bone Diseases, Metabolic/enzymology , Bone Diseases, Metabolic/therapy , Humans , Infant, Extremely Low Birth Weight , Infant, Newborn , Infant, Premature, Diseases/enzymology , Infant, Premature, Diseases/therapy , Nutritional Support , Rickets/enzymology , Rickets/therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...